UP421
Type 1 Diabetes
Pre-ClinicalInvestigator Sponsored Trial
Key Facts
Indication
Type 1 Diabetes
Phase
Pre-Clinical
Status
Investigator Sponsored Trial
Company
About Sana Biotechnology
Sana Biotechnology aims to create and deliver engineered cells as medicines to address the root causes of disease. The company has established two complementary, proprietary technology platforms designed to overcome the major hurdles of immune rejection and targeted in vivo delivery that have limited the field. Its strategy focuses on advancing a pipeline of potentially curative therapies for type 1 diabetes and B-cell malignancies, with its most advanced programs now entering early clinical testing. Despite being pre-revenue, Sana has assembled a seasoned leadership team and secured significant capital to pursue its ambitious vision.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |